







OPTIMISATION OF ANTI-INTERLEUKIN BIOLOGICAL THERAPIES IN PSORIASIS PATIENT ABOVE 100 KG

J. Preciado Goldaracena¹, N. Larrea Goñi¹, M. Coma Punset¹, J. Polo García¹, J.I. Yanguas Bayona², C. Fontela Bulnes¹, R. San Miguel Elcano¹, J. Fernández González¹, R. Juanbeltz Zurbano¹, J. Alfaro Basarte¹.

> ¹Complejo Hospitalario de Navarra, Pharmacy, Pamplona, Spain. ²Complejo Hospitalario de Navarra, Dermatology, Pamplona, Spain.


PURPOSE

To describe our experience and assess the clinical response and economic impact of switching from ustekinumab to secukinumab in moderate-severe plaque psoriasis patients above 100 kg in maintenance phase with optimal (PASI<5) or suboptimal (PASI 5-10) response.

MATERIAL AND METHODS

Retrospective, observational study of psoriasis patients previously treated with ustekinumab double dose, from March to October 2016.

| Variables | Sex, age, weight, diagnosis, previous therapy with ustekinumab 90 mg quarterly and Psoriasis Area and Severity Index (PASI). |
|-------------------|--|
| Clinical response | PASI no change in patients with optimal response. PASI improvement in those with suboptimal response. |
| Economic impact | Difference between patient-year cost of ustekinumab double dose vs secukinumab in order to calculate the patient-year savings. |



- 5-10: Secukinumab 300 mg with reduced induction (weeks 1,3) followed by monthly administration.

< 5 : Secukinumab 300 mg without induction (monthly administration).

RESULTS

6 patients, 83.3% men, mean age 55 (49-67), were evaluated.

<u>Clinical response</u>

| Ustekinumab response | Patients | Mean PASI in maintenance | Patients with PASI improvement |
|-------------------------|----------|-----------------------------|--|
| Suboptimal | 3 | 6.8 | 2 achieved improvement. The third has not yet been evaluated |
| Optimal | 3 | 3.1 | All of them achieved improvement |

| <u>Economic impact</u> | Ustekinumab patient-year cost | Secukinumab patient-year cost | Patient-year savings. |
|--|----------------------------------|----------------------------------|-----------------------|
| Patient with secukinumab reduced induction | 26.429,4 € | 17.457,72€ | 8.971,68€ |
| Patient without secukinumab induction | 26.429,4 € | 16.210,74€ | 10.218,66€ |

CONCLUSION

- Optimisation of anti-interleukin biological agents is a strategy to manage psoriasis patients above 100 kg according to criteria of clinical activity and costs in our settings.
- Our experience using alternative dosing of secukinumab induction depending on PASI in the change moment revealed a decrease in costs providing direct savings for the hospital while maintaining treatment efficacy.